
Novo Nordisk Faces a Setback: Ozempic Pill Falls Short in Alzheimer's Trials
Novo Nordisk's recent revelations about the Ozempic pill's failure in Alzheimer's trials have sent its stock tumbling. This downturn not only highlights the volatility of pharmaceutical innovations but also raises complex questions about the future of treatments for neurodegenerative diseases.
Read full article




























